{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:15:09Z","timestamp":1753892109696,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Context<\/jats:title><jats:p>Wolfram syndrome (WS) is an autosomal recessive neurodegenerative disorder caused by pathogenic variants in the <jats:italic>WFS1<\/jats:italic> gene. It is characterized by central diabetes insipidus, juvenile-onset diabetes mellitus (DM), optic atrophy (OA), and deafness. The natural history of WS is variable, even within the same family and with the same variant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To report the phenotypes of five patients of Druze origin, all carrying the same autosomal recessive pathogenic variant in the <jats:italic>WFS1<\/jats:italic> gene.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients &amp;amp; methods<\/jats:title><jats:p>Five patients belonging to three core families were enrolled. Clinical, biochemical, and genetic data were retrieved retrospectively from their medical files.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All five patients carried the same previously reported homozygous <jats:italic>WFS1<\/jats:italic> pathogenic variant: c.2649del, p.Phe884fs. In all patients, the first presentation was DM at a mean age of 5.2 years (range 4\u20137), diagnosed initially as type 1 DM with negative anti-pancreatic autoantibodies, and all were treated with insulin by either pump or multiple injections. All five patients had OA that appeared at a mean age of 12.3 years (range 4\u201330). Three had hearing loss and neurological involvement, and none had diabetes insipidus. One patient was treated with a glucagon-like peptide 1 receptor agonist with a good response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This is the first report of a founder pathogenic variant in the <jats:italic>WFS1<\/jats:italic> gene in the Druze population in Israel. Our findings imply that molecular analysis is warranted in children presenting with DM and negative pancreatic antibodies. The identified variant should be considered for genetic testing in individuals of Druze ancestry diagnosed with young-onset non-autoimmune diabetes. Early diagnosis of WS is important for therapeutic approaches, especially since novel medications are becoming available.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1525846","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T06:59:13Z","timestamp":1738133953000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of a pathogenic founder variant in the WFS1 gene that causes Wolfram syndrome in the Druze population"],"prefix":"10.3389","volume":"13","author":[{"given":"Inbal","family":"Halabi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yardena","family":"Tenenbaum-Rakover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Sagi-Dain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilana","family":"Koren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e240091","DOI":"10.20945\/2359-4292-2024-0091","article-title":"Insights from a wolfram syndrome cohort: clinical and molecular findings from a specialized diabetes reference center","volume":"68","author":"Lopes","year":"2024","journal-title":"Arch Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11892-015-0702-6","article-title":"Wolfram syndrome: diagnosis, management, and treatment","volume":"16","author":"Urano","year":"2016","journal-title":"Curr Diab Rep"},{"key":"B3","first-page":"715","article-title":"Diabetes mellitus and simple optic atrophy among siblings","volume":"13","author":"Wolfram","year":"1938","journal-title":"Mayo Clin Proc"},{"key":"B4","doi-asserted-by":"publisher","first-page":"9412676","DOI":"10.1155\/2018\/9412676","article-title":"Wolfram syndrome: a case report and review of clinical manifestations, genetics pathophysiology, and potential therapies","volume":"18","author":"Toppings","year":"2018","journal-title":"Case Rep Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1210\/jc.2002-030015","article-title":"Diabetes mellitus and optic atrophy: a study of wolfram syndrome in the Lebanese population","volume":"89","author":"Medlej","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40618-013-0039-4","article-title":"Phenotypical and genotypical expression of wolfram syndrome in 12 patients from a Sicilian district where this syndrome might not be so infrequent as generally expected","volume":"37","author":"Lombardo","year":"2014","journal-title":"J Endocrinol Invest"},{"key":"B7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12967-019-1993-1","article-title":"Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives","volume":"17","author":"Pallotta","year":"2019","journal-title":"J Transl Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"26330040211039518","DOI":"10.1177\/26330040211039518","article-title":"Wolfram syndrome: new pathophysiological insights and therapeutic strategies","volume":"2","author":"Mishra","year":"2021","journal-title":"Ther Adv Rare Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1198171","DOI":"10.3389\/fgene.2023.1198171","article-title":"Genotype and clinical characteristics of patients with wolfram syndrome and WFS1-related disorders","volume":"14","author":"Lee","year":"2023","journal-title":"Front Genet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.2337\/db16-1296","article-title":"Dominant ER stress\u2013inducing WFS1 mutations underlie a genetic syndrome of neonatal\/infancy-onset diabetes, congenital sensorineural deafness, and congenital cataracts","volume":"66","author":"De Franco","year":"2017","journal-title":"Diabetes"},{"key":"B11","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1172\/JCI39678","article-title":"Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells","volume":"120","author":"Fonseca","year":"2010","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1171091","DOI":"10.3389\/fcdhc.2023.1171091","article-title":"GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder","volume":"4","author":"Panfili","year":"2023","journal-title":"Front Clin Diabetes Healthc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/pr.2018.17","article-title":"Genetic and clinical aspects of wolfram syndrome 1, a severe neurodegenerative disease","volume":"83","author":"Rigoli","year":"2018","journal-title":"Pediatr Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/gim.2012.180","article-title":"Genotypic classification of patients with wolfram syndrome: insights into the natural history of the disease and correlation with phenotype","volume":"15","author":"de Heredia","year":"2013","journal-title":"Genet Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e578","DOI":"10.1212\/NXG.0000000000000578","article-title":"Mild phenotype of wolfram syndrome associated with a common pathogenic variant is predicted by a structural model of wolframin","volume":"7","author":"Wilf-Yarkoni","year":"2021","journal-title":"Neurol Genet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/sj.ejhg.5201491","article-title":"Mutation analysis of the WFS1 gene in seven Danish wolfram syndrome families; four new mutations identified","volume":"13","author":"Hansen","year":"2005","journal-title":"Eur J Hum Genet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/ejhg.2014.218","article-title":"Genotyping of geographically diverse druze trios reveals substructure and a recent bottleneck","volume":"23","author":"Zidan","year":"2014","journal-title":"Eur J Hum Genet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41390-019-0487-4","article-title":"Wolfram syndrome 1 in the Italian population: genotype\u2013phenotype correlations","volume":"87","author":"Rigoli","year":"2020","journal-title":"Pediatr Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.2337\/dc07-0380","article-title":"Microvascular diabetes complications in wolfram syndrome (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness [DIDMOAD]): an age- and duration-matched comparison with common type 1 diabetes","volume":"30","author":"Cano","year":"2007","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"398","DOI":"10.5603\/EP.2014.0055","article-title":"False diagnosis of type 1 diabetes mellitus and its complications in wolfram syndrome\u2013is it the reason for the low number of reported cases of this abnormality?","volume":"65","author":"Homa","year":"2014","journal-title":"Endokrynol Pol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/WNO.0000000000002232","article-title":"Family planning in genetic optic atrophies in Israel, a case series and a discussion of ethical considerations","author":"Rozanes","year":"2024","journal-title":"J Neuroophthalmol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/ajmg.a.31809","article-title":"Identification of novel mutations in WFS1 and genotype\u2013phenotype correlation in wolfram syndrome","author":"Cano","year":"2007","journal-title":"Am J Med Genet A"},{"key":"B23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.aace.2022.01.001","article-title":"Two cases of wolfram syndrome who were initially diagnosed with type 1 diabetes","volume":"8","author":"Silvestri","year":"2022","journal-title":"AACE Clin Case Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"101452","DOI":"10.1016\/j.ajoc.2022.101452","article-title":"Wolfram syndrome: a case report of two sisters wolfram syndrome: case report of two sisters","volume":"26","author":"Rotsos","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.3390\/ijerph19063225","article-title":"Wolfram syndrome 1: from genetics to therapy","volume":"19","author":"Rigoli","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1007\/s00125-023-05905-8","article-title":"GLP-1R agonists demonstrate potential to treat wolfram syndrome in human preclinical models","volume":"66","author":"Gorgogietas","year":"2023","journal-title":"Diabetologia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"23247096221150631","DOI":"10.1177\/23247096221150631","article-title":"A pair of siblings with wolfram syndrome: a review of the literature and treatment options","volume":"11","author":"Png","year":"2023","journal-title":"J Investig Med High Impact Case Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"755365","DOI":"10.3389\/fped.2021.755365","article-title":"Case report: off-label liraglutide use in children with wolfram syndrome type 1: extensive characterization of four patients","volume":"9","author":"Frontino","year":"2021","journal-title":"Front Pediatr"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00125-009-1344-5","article-title":"A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion","volume":"52","author":"Sch\u00e4fer","year":"2009","journal-title":"Diabetologia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.3390\/cells10113193","article-title":"Early intervention and lifelong treatment with GLP1 receptor agonist liraglutide in a wolfram syndrome rat model with an emphasis on visual neurodegeneration, sensorineural hearing loss and diabetic phenotype","volume":"10","author":"Jagom\u00e4e","year":"2021","journal-title":"Cells"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1002511","DOI":"10.1371\/journal.pbio.1002511","article-title":"Role of mitochondrial dynamics in neuronal development: mechanism for wolfram syndrome","volume":"14","author":"Cagalinec","year":"2016","journal-title":"PLoS Biol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"eaaq1380","DOI":"10.1126\/scisignal.aaq1380","article-title":"ER-mitochondria cross-talk is regulated by the Ca2+ sensor NCS1 and is impaired in wolfram syndrome","volume":"11","author":"Angebault","year":"2018","journal-title":"Sci Signal"},{"key":"B34","doi-asserted-by":"publisher","first-page":"eabh3763","DOI":"10.1126\/scitranslmed.abh3763","article-title":"Activation of the sigma-1 receptor chaperone alleviates symptoms of wolfram syndrome in preclinical models","volume":"14","author":"Crouzier","year":"2022","journal-title":"Sci Transl Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.4103\/NRR.NRR-D-23-02021","article-title":"Tale of mitochondria and mitochondria-associated ER membrane in patient-derived neuronal models of wolfram syndrome","volume":"20","author":"Aubry","year":"2025","journal-title":"Neural Regen Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.stemcr.2023.04.002","article-title":"Depletion of WFS1 compromises mitochondrial function in hiPSC-derived neuronal models of wolfram syndrome","volume":"18","author":"Zatyka","year":"2023","journal-title":"Stem Cell Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1038\/s41467-024-50502-x","article-title":"ER Calcium depletion as a key driver for impaired ER-to-mitochondria calcium transfer and mitochondrial dysfunction in wolfram syndrome","volume":"15","author":"Liiv","year":"2024","journal-title":"Nat Commun"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1525846\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T06:59:16Z","timestamp":1738133956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1525846\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":37,"alternative-id":["10.3389\/fped.2025.1525846"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1525846","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"article-number":"1525846"}}